3.4.21.92	(4R)-3-(4-methoxyphenyl)-4-(pent-4-yn-1-yl)oxetan-2-one	inhibitor efficiently alters the oligomerization of the enzyme to smaller species, almost quantitative shift from the tetradecamer to the heptamer with modification of 35% of the active sites	199410	
3.4.21.92	1-(1,1-dioxido-1,2-thiazetidin-2-yl)hexan-1-one	alkyne-free beta-sultam analogue. Treatment leads to dehydroalanine formation of the active site serine. The reaction proceeds through sulfonylation and subsequent elimination, thereby obliterating the catalytic charge relay system	199414	
3.4.21.92	1-(4-benzoyl-1,1-dioxido-1,2-thiazetidin-2-yl)ethanone	alkyne-free beta-sultam analogue. Treatment leads to dehydroalanine formation of the active site serine. The reaction proceeds through sulfonylation and subsequent elimination, thereby obliterating the catalytic charge relay system	199412	
3.4.21.92	1-[4-(4-ethynylbenzoyl)-1,1-dioxido-1,2-thiazetidin-2-yl]ethanone	treatment results in almost instant covalent modification of all 14 active sites and complete inhibition of peptidase activity	199411	
3.4.21.92	1-[4-(4-ethynylbenzoyl)-1,1-dioxido-1,2-thiazetidin-2-yl]undec-10-en-1-one	inhibitor efficiently alters the oligomerization of the enzyme to smaller species, almost quantitative shift from the tetradecamer to the heptamer with modification of 63% of the active sites	199409	
3.4.21.92	1-[4-benzoyl-1,1-dioxido-1,2-thiazetidin-2-yl]undec-10-en-1-one	alkyne-free beta-sultam analogue. Treatment leads to dehydroalanine formation of the active site serine. The reaction proceeds through sulfonylation and subsequent elimination, thereby obliterating the catalytic charge relay system	199413	
3.4.21.92	3-(4-methoxyphenyl)-4-(pent-4-ynyl)oxetan-2-one	shows stronger inhibitory effect	73175	
3.4.21.92	3-(non-8-ynyl)-4-(pent-4-ynyl)oxetan-2-one	exerts the weakest effect on peptidase activity	73181	
3.4.21.92	3-butyl-4-(pent-4-ynyl)oxetan-2-one	shows stronger inhibitory effect	73190	
3.4.21.92	CAANDENYALAA	-	141886